Globus Medical (NYSE:GMED) Director Ann Rhoads Sells 5,000 Shares of Stock

Globus Medical, Inc. (NYSE:GMED) Director Ann Rhoads sold 5,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the sale, the director directly owned 35,384 shares in the company, valued at approximately $3,007,640. The trade was a 12.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Globus Medical Stock Performance

GMED opened at $81.13 on Friday. Globus Medical, Inc. has a one year low of $60.36 and a one year high of $101.40. The stock has a market capitalization of $10.89 billion, a PE ratio of 20.75, a P/E/G ratio of 1.40 and a beta of 0.98. The business’s 50 day moving average price is $77.44 and its 200 day moving average price is $83.29.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.03. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The company had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. During the same quarter last year, the firm earned $1.18 earnings per share. The firm’s quarterly revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities research analysts forecast that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors have recently modified their holdings of the company. Paradigm Capital Management Inc. NY acquired a new position in Globus Medical during the 2nd quarter worth approximately $70,042,000. American Capital Management Inc. purchased a new stake in shares of Globus Medical in the 2nd quarter valued at approximately $51,599,000. Hawk Ridge Capital Management LP acquired a new stake in shares of Globus Medical in the 1st quarter valued at $43,078,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Globus Medical by 107.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock valued at $78,656,000 after purchasing an additional 471,875 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GMED has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. UBS Group began coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price target for the company. Truist Financial reduced their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Royal Bank Of Canada reduced their price target on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, October 1st. Finally, Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.46.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical reported third-quarter EPS of $1.23, topping the $1.20 consensus and rising from $1.18 a year earlier. The company also increased its share-repurchase authorization by $500 million, which could support shareholder returns. Third-quarter results and repurchase program
• Positive Sentiment: The company’s acquisition of Synaptive Medical adds cranial-neurosurgery technology and may strengthen its position in cranial procedures. Globus Medical acquires neurosurgery technology
• Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her reported holdings by 12.38%. A single insider sale does not necessarily indicate a change in the company’s outlook. SEC ownership filing
• Negative Sentiment: Quarterly revenue was $763.7 million, below analysts’ $792.4 million estimate and down 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion also trails the $3.2 billion consensus; EPS guidance of $4.95–$5.05 is broadly in line with the $5.00 estimate. The sales miss and softer revenue outlook likely outweighed the EPS beat. Quarterly results and guidance

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.